Product Code: DMKC12804
The value of the venous thromboembolism (VTE) market is expected to grow rapidly as the approvals of antidotes for the novel oral anticoagulant (NOAC) drugs are secured and physician acceptance of these drugs rises.
This report addresses the following questions:
- Which patient subgroups and markets will have the largest impact on VTE sales?
- How will the approval of antidotes affect the uptake of the NOAC drug class?
- What are the most commonly prescribed therapies for VTE patients?
- How will Pradaxa's first-to-market antidote affect the market shares of other NOAC molecules?
- What are the growth drivers and resistors for the NOAC and vitamin K antagonist drug classes during 2015-24?
- How do the prescribing trends correlate with current recommendations from clinical guidelines?
TABLE OF CONTENTS
FORECAST: VENOUS THROMBOEMBOLISM
- 1. Executive Summary
- 2. Market Overview and Trends
- 3. Market Definition and Methodology
- 4. Eliquis (apixaban)
- 5. Pradaxa (dabigatran)
- 6. Savaysa (edoxaban)
- 7. Xarelto (rivaroxaban)
- 8. Primary Research Methodology
TREATMENT: VENOUS THROMBOEMBOLISM
- 9. Executive Summary
- 10. Primary Research Methodology
- 11. Disease Definition and Diagnosis
- 12. Country Treatment Trees
- 13. Current Treatment Options
- 14. Prescribing Trends
EPIDEMIOLOGY: VENOUS THROMBOEMBOLISM
- 15. Executive Summary
- 16. Sources and Methodology
- 17. Forecast
- 18. Epidemiologist Insight.
- 19. Strengths and Limitations
MARKETED DRUGS: VENOUS THROMBOEMBOLISM
- 20. Executive Summary
- 21. Product Overview
- 22. Product profile: Coumadin
- 23. Product profile: Eliquis
- 24. Product profile: Lovenox
- 25. Product profile: Pradaxa
- 26. Product profile: Savaysa
- 27. Product profile: Xarelto
PIPELINE: VENOUS THROMBOEMBOLISM
- 28. Executive Summary
- 29. Clinical Pipeline Overview
- 30. Target Product Profile
- 31. Product profile (late stage): betrixaban